Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report) traded down 0.2% during trading on Wednesday . The company traded as low as $0.94 and last traded at $0.94. 6,200 shares were traded during mid-day trading, an increase of 12% from the average session volume of 5,541 shares. The stock had previously closed at $0.9420.
Spectral Diagnostics Price Performance
The stock has a market capitalization of $275.83 million, a PE ratio of -9.40 and a beta of 0.11. The company’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $0.99.
Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.54 million.
About Spectral Diagnostics
Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
See Also
- Five stocks we like better than Spectral Diagnostics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
